{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:24:09Z","timestamp":1788269049062,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"DOI":"10.1007\/s10557-026-07938-8","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:11:35Z","timestamp":1788268295000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Empagliflozin Improves Atherosclerosis by Promoting Mitophagy in Endothelial Cells"],"prefix":"10.1007","author":[{"given":"Longlong","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoyu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"issue":"11","key":"7938_CR1","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.clinthera.2023.09.020","volume":"45","author":"L Nedkoff","year":"2023","unstructured":"Nedkoff L, Briffa T, Zemedikun D, Herrington S, Wright FL. Global Trends in Atherosclerotic Cardiovascular Disease. Clin Ther. 2023;45(11):1087\u201391. https:\/\/doi.org\/10.1016\/j.clinthera.2023.09.020.","journal-title":"Clin Ther"},{"issue":"6","key":"7938_CR2","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s10557-024-07642-5","volume":"39","author":"X Zhou","year":"2025","unstructured":"Zhou X, Wang H, Yan B, et al. Ferroptosis in Cardiovascular Diseases and Ferroptosis-Related Intervention Approaches. Cardiovasc Drugs Ther. 2025;39(6):1521\u201348. https:\/\/doi.org\/10.1007\/s10557-024-07642-5.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"6","key":"7938_CR3","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s10557-024-07659-w","volume":"39","author":"B Ye","year":"2025","unstructured":"Ye B, Cai X, Liang X, et al. Emodin Suppresses NLRP3\/GSDMD-induced Inflammation via the TLR4\/MyD88\/NF-\u03baB Signaling Pathway in Atherosclerosis. Cardiovasc Drugs Ther. 2025;39(6):1289\u2013301. https:\/\/doi.org\/10.1007\/s10557-024-07659-w.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"10","key":"7938_CR4","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1161\/circresaha.118.313816","volume":"123","author":"K Kobiyama","year":"2018","unstructured":"Kobiyama K, Ley K, Atherosclerosis. Circ Res. 2018;123(10):1118\u201320. https:\/\/doi.org\/10.1161\/circresaha.118.313816.","journal-title":"Circ Res"},{"issue":"1","key":"7938_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","volume":"5","author":"P Libby","year":"2019","unstructured":"Libby P, Buring JE, Badimon L, et al. Atherosclerosis Nat Rev Dis Primers. 2019;5(1):56. https:\/\/doi.org\/10.1038\/s41572-019-0106-z.","journal-title":"Atherosclerosis Nat Rev Dis Primers"},{"issue":"3","key":"7938_CR6","doi-asserted-by":"publisher","first-page":"e56635","DOI":"10.7759\/cureus.56635","volume":"16","author":"Y Almohtasib","year":"2024","unstructured":"Almohtasib Y, Fancher AJ, Sawalha K. Emerging Trends in Atherosclerosis: Time to Address Atherosclerosis From a Younger Age. Cureus. 2024;16(3):e56635. https:\/\/doi.org\/10.7759\/cureus.56635.","journal-title":"Cureus"},{"issue":"5","key":"7938_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40256-019-00391-z","volume":"20","author":"L Nesti","year":"2020","unstructured":"Nesti L, Mengozzi A, Natali A, Statins LDLC, Control. Cardiovascular Disease Prevention, and Atherosclerosis Progression: A Clinical Perspective. Am J Cardiovasc Drugs. 2020;20(5):405\u201312. https:\/\/doi.org\/10.1007\/s40256-019-00391-z.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"7938_CR8","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12951-025-03384-0","volume":"23","author":"L Tu","year":"2025","unstructured":"Tu L, Zou Z, Yang Y, et al. Targeted drug delivery systems for atherosclerosis. J Nanobiotechnol. 2025;23(1):306. https:\/\/doi.org\/10.1186\/s12951-025-03384-0.","journal-title":"J Nanobiotechnol"},{"key":"7938_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.pharmthera.2018.10.004","volume":"195","author":"A Liu","year":"2019","unstructured":"Liu A, Wu Q, Guo J, et al. Statins: Adverse reactions, oxidative stress and metabolic interactions. Pharmacol Ther. 2019;195:54\u201384. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.10.004.","journal-title":"Pharmacol Ther"},{"key":"7938_CR10","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.2147\/jir.S309427","volume":"14","author":"Y Liu","year":"2021","unstructured":"Liu Y, Wu M, Xu B, Kang L. Empagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model. J Inflamm Res. 2021;14:2277\u201387. https:\/\/doi.org\/10.2147\/jir.S309427.","journal-title":"J Inflamm Res"},{"issue":"2","key":"7938_CR11","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s00125-016-4158-2","volume":"60","author":"JH Han","year":"2017","unstructured":"Han JH, Oh TJ, Lee G, et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE (-\/-) mice fed a western diet. Diabetologia. 2017;60(2):364\u201376. https:\/\/doi.org\/10.1007\/s00125-016-4158-2.","journal-title":"Diabetologia"},{"key":"7938_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ijcard.2022.07.048","volume":"367","author":"J Fu","year":"2022","unstructured":"Fu J, Xu H, Wu F, et al. Empagliflozin inhibits macrophage inflammation through AMPK signaling pathway and plays an anti-atherosclerosis role. Int J Cardiol. 2022;367:56\u201362. https:\/\/doi.org\/10.1016\/j.ijcard.2022.07.048.","journal-title":"Int J Cardiol"},{"issue":"1","key":"7938_CR13","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1186\/s12872-025-04890-7","volume":"25","author":"Z Wang","year":"2025","unstructured":"Wang Z, Liu S, Shi J, et al. Empagliflozin ameliorates RSL3-induced ferroptosis in vascular endothelial cells via the NRF2\/HO-1 pathway. BMC Cardiovasc Disord. 2025;25(1):437. https:\/\/doi.org\/10.1186\/s12872-025-04890-7.","journal-title":"BMC Cardiovasc Disord"},{"issue":"3","key":"7938_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41569-022-00770-1","volume":"20","author":"E Trimm","year":"2023","unstructured":"Trimm E, Red-Horse K. Vascular endothelial cell development and diversity. Nat Rev Cardiol. 2023;20(3):197\u2013210. https:\/\/doi.org\/10.1038\/s41569-022-00770-1.","journal-title":"Nat Rev Cardiol"},{"key":"7938_CR15","doi-asserted-by":"publisher","unstructured":"Bu LL, Yuan HH, Xie LL, et al. New dawn for atherosclerosis: vascular endothelial cell senescence and death. Int J Mol Sci. 2023;24(20). https:\/\/doi.org\/10.3390\/ijms242015160.","DOI":"10.3390\/ijms242015160"},{"key":"7938_CR16","doi-asserted-by":"publisher","first-page":"1493948","DOI":"10.3389\/fphar.2024.1493948","volume":"15","author":"Y Ma","year":"2024","unstructured":"Ma Y, Song D, Yuan J, et al. Alisol A inhibits and stabilizes atherosclerotic plaques by protecting vascular endothelial cells. Front Pharmacol. 2024;15:1493948. https:\/\/doi.org\/10.3389\/fphar.2024.1493948.","journal-title":"Front Pharmacol"},{"issue":"10","key":"7938_CR17","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1089\/dna.2022.0249","volume":"41","author":"Y Chen","year":"2022","unstructured":"Chen Y, Qin W, Li L, Wu P, Wei D. Mitophagy: Critical Role in Atherosclerosis Progression. DNA Cell Biol. 2022;41(10):851\u201360. https:\/\/doi.org\/10.1089\/dna.2022.0249.","journal-title":"DNA Cell Biol"},{"issue":"3","key":"7938_CR18","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s10557-025-07785-z","volume":"40","author":"Y Li","year":"2026","unstructured":"Li Y, Feng C, Lin H, et al. Protective role of HOXB5-orchestrated mitochondrial homeostasis and mitophagy in cardiomyocytes after ischemia-reperfusion via transcriptionally activating Sirt5. Cardiovasc Drugs Ther. 2026;40(3):861\u201382. https:\/\/doi.org\/10.1007\/s10557-025-07785-z.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"7938_CR19","doi-asserted-by":"publisher","first-page":"113688","DOI":"10.1016\/j.yexcr.2023.113688","volume":"429","author":"S Liu","year":"2023","unstructured":"Liu S, Zhao Y, Yao H, et al. DRP1 knockdown and atorvastatin alleviate ox-LDL-induced vascular endothelial cells injury: DRP1 is a potential target for preventing atherosclerosis. Exp Cell Res. 2023;429(2):113688. https:\/\/doi.org\/10.1016\/j.yexcr.2023.113688.","journal-title":"Exp Cell Res"},{"issue":"7","key":"7938_CR20","doi-asserted-by":"publisher","first-page":"e0132499","DOI":"10.1371\/journal.pone.0132499","volume":"10","author":"W Wu","year":"2015","unstructured":"Wu W, Xu H, Wang Z, et al. Pink1-Parkin-Mediated Mitophagy Protects Mitochondrial Integrity and Prevents Metabolic Stress-Induced Endothelial Injury. PLoS ONE. 2015;10(7):e0132499. https:\/\/doi.org\/10.1371\/journal.pone.0132499.","journal-title":"PLoS ONE"},{"issue":"1","key":"7938_CR21","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12944-024-02263-1","volume":"23","author":"Q Hu","year":"2024","unstructured":"Hu Q, Li C, Zhang T, et al. Dihydromyricetin suppresses endothelial NLRP3 inflammasome activation and attenuates atherogenesis by promoting mitophagy. Lipids Health Dis. 2024;23(1):279. https:\/\/doi.org\/10.1186\/s12944-024-02263-1.","journal-title":"Lipids Health Dis"},{"issue":"9","key":"7938_CR22","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1002\/ptr.7854","volume":"37","author":"X Wang","year":"2023","unstructured":"Wang X, Zhang M, Mao C, et al. Icariin alleviates ferroptosis-related atherosclerosis by promoting autophagy in xo-LDL-induced vascular endothelial cell injury and atherosclerotic mice. Phytother Res. 2023;37(9):3951\u201363. https:\/\/doi.org\/10.1002\/ptr.7854.","journal-title":"Phytother Res"},{"issue":"1","key":"7938_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s13105-023-00974-0","volume":"80","author":"H Xu","year":"2024","unstructured":"Xu H, Fu J, Tu Q, et al. The SGLT2 inhibitor empagliflozin attenuates atherosclerosis progression by inducing autophagy. J Physiol Biochem. 2024;80(1):27\u201339. https:\/\/doi.org\/10.1007\/s13105-023-00974-0.","journal-title":"J Physiol Biochem"},{"key":"7938_CR24","doi-asserted-by":"publisher","unstructured":"Hsieh PL, Chu PM, Cheng HC, et al. Dapagliflozin mitigates doxorubicin-caused myocardium damage by regulating akt-mediated oxidative stress, cardiac remodeling, and inflammation. Int J Mol Sci. 2022;23(17). https:\/\/doi.org\/10.3390\/ijms231710146.","DOI":"10.3390\/ijms231710146"},{"key":"7938_CR25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3389\/fgene.2012.00297","volume":"3","author":"K Palikaras","year":"2012","unstructured":"Palikaras K, Tavernarakis N. Mitophagy in neurodegeneration and aging. Front Genet. 2012;3:297. https:\/\/doi.org\/10.3389\/fgene.2012.00297.","journal-title":"Front Genet"},{"issue":"10","key":"7938_CR26","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1093\/eurheartj\/ehab600","volume":"43","author":"AP DeFilippis","year":"2022","unstructured":"DeFilippis AP, Trainor PJ, Thanassoulis G, et al. Atherothrombotic factors and atherosclerotic cardiovascular events: the multi-ethnic study of atherosclerosis. Eur Heart J. 2022;43(10):971\u201381. https:\/\/doi.org\/10.1093\/eurheartj\/ehab600.","journal-title":"Eur Heart J"},{"issue":"6","key":"7938_CR27","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1024\/0301-1526\/a000969","volume":"50","author":"JJF Belch","year":"2021","unstructured":"Belch JJF, Brodmann M, Baumgartner I, et al. Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease. Vasa. 2021;50(6):401\u201311. https:\/\/doi.org\/10.1024\/0301-1526\/a000969.","journal-title":"Vasa"},{"issue":"6","key":"7938_CR28","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1097\/cm9.0000000000002057","volume":"136","author":"X Zhou","year":"2023","unstructured":"Zhou X, Li Z, Liu H, et al. Antithrombotic therapy and bleeding risk in the era of aggressive lipid-lowering: current evidence, clinical implications, and future perspectives. Chin Med J (Engl). 2023;136(6):645\u201352. https:\/\/doi.org\/10.1097\/cm9.0000000000002057.","journal-title":"Chin Med J (Engl)"},{"issue":"5","key":"7938_CR29","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/ndt\/gfab330","volume":"37","author":"KL Hudkins","year":"2022","unstructured":"Hudkins KL, Li X, Holland AL, Swaminathan S, Alpers CE. Regression of diabetic nephropathy by treatment with empagliflozin in BTBR ob\/ob mice. Nephrol Dial Transpl. 2022;37(5):847\u201359. https:\/\/doi.org\/10.1093\/ndt\/gfab330.","journal-title":"Nephrol Dial Transpl"},{"issue":"9","key":"7938_CR30","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.7150\/thno.54498","volume":"11","author":"Z Liu","year":"2021","unstructured":"Liu Z, Ma X, Ilyas I, et al. Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics. Theranostics. 2021;11(9):4502\u201315. https:\/\/doi.org\/10.7150\/thno.54498.","journal-title":"Theranostics"},{"key":"7938_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2023.03.011","volume":"371","author":"H Hao","year":"2023","unstructured":"Hao H, Li Z, Qiao SY, et al. Empagliflozin ameliorates atherosclerosis via regulating the intestinal flora. Atherosclerosis. 2023;371:32\u201340. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.03.011.","journal-title":"Atherosclerosis"},{"issue":"4","key":"7938_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.55729\/2000-9666.1505","volume":"15","author":"M Maik","year":"2025","unstructured":"Maik M, Ibtisam M, Sheikh S, et al. The Role of SGLT2 Inhibitors in Atherosclerosis: A Systematic Review. J Community Hosp Intern Med Perspect. 2025;15(4):29\u201333. https:\/\/doi.org\/10.55729\/2000-9666.1505.","journal-title":"J Community Hosp Intern Med Perspect"},{"issue":"7","key":"7938_CR33","doi-asserted-by":"publisher","first-page":"e0353564","DOI":"10.1371\/journal.pone.0353564","volume":"21","author":"F Cokro","year":"2026","unstructured":"Cokro F, Sauriasari R, Tahapary DL, et al. Glycaemic, cardiorenal, and lipid parameters associated with SGLT2 inhibitors use in Indonesian patients with type 2 diabetes: 12-month multicenter real-world study. PLoS ONE. 2026;21(7):e0353564. https:\/\/doi.org\/10.1371\/journal.pone.0353564.","journal-title":"PLoS ONE"},{"key":"7938_CR34","doi-asserted-by":"publisher","unstructured":"Szekeres Z, Toth K, Szabados E. The effects of SGLT2 inhibitors on lipid metabolism. Metabolites. 2021;11(2). https:\/\/doi.org\/10.3390\/metabo11020087.","DOI":"10.3390\/metabo11020087"},{"issue":"1","key":"7938_CR35","doi-asserted-by":"publisher","first-page":"e0245797","DOI":"10.1371\/journal.pone.0245797","volume":"16","author":"GM Sanda","year":"2021","unstructured":"Sanda GM, Stancu CS, Deleanu M, et al. Aggregated LDL turn human macrophages into foam cells and induce mitochondrial dysfunction without triggering oxidative or endoplasmic reticulum stress. PLoS ONE. 2021;16(1):e0245797. https:\/\/doi.org\/10.1371\/journal.pone.0245797.","journal-title":"PLoS ONE"},{"key":"7938_CR36","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.bbrc.2021.08.023","volume":"577","author":"J Hua","year":"2021","unstructured":"Hua J, Gao Z, Zhong S, et al. CISD1 protects against atherosclerosis by suppressing lipid accumulation and inflammation via mediating Drp1. Biochem Biophys Res Commun. 2021;577:80\u20138. https:\/\/doi.org\/10.1016\/j.bbrc.2021.08.023.","journal-title":"Biochem Biophys Res Commun"},{"issue":"Pt 2","key":"7938_CR37","doi-asserted-by":"publisher","first-page":"145011","DOI":"10.1016\/j.ijbiomac.2025.145011","volume":"318","author":"G Zheng","year":"2025","unstructured":"Zheng G, Xie J, Yan Z, et al. Uncovering the mechanism of Buyang Huanwu Decoction in regulating mitochondrial dysfunction to alleviate atherosclerosis: BTK, PREPL, and P2RX7 proteins play key roles. Int J Biol Macromol. 2025;318(Pt 2):145011. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.145011.","journal-title":"Int J Biol Macromol"},{"issue":"19","key":"7938_CR38","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1016\/j.molcel.2023.08.021","volume":"83","author":"L Uoselis","year":"2023","unstructured":"Uoselis L, Nguyen TN, Lazarou M. Mitochondrial degradation: Mitophagy and beyond. Mol Cell. 2023;83(19):3404\u201320. https:\/\/doi.org\/10.1016\/j.molcel.2023.08.021.","journal-title":"Mol Cell"},{"issue":"3","key":"7938_CR39","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3390\/ph18030405","volume":"18","author":"A Alhaddad","year":"2025","unstructured":"Alhaddad A, Mosalam EM, AboShabaan HS, et al. Mechanistic and Molecular Insights into Empagliflozin\u2019s Role in Ferroptosis and Inflammation Trajectories in Acetaminophen-Induced Hepatotoxicity. Pharmaceuticals. 2025;18(3):405.","journal-title":"Pharmaceuticals"},{"issue":"10","key":"7938_CR40","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1093\/jpp\/rgaf051","volume":"77","author":"N Hendawy","year":"2025","unstructured":"Hendawy N, El-Sayed SM, AbdelWahed DM, Salaheldin SH, Abuelezz SA. Empagliflozin attenuates pyroptosis by regulating thioredoxin-NLRP3 inflammasome axis in a high fat cholesterol diet\/streptozotocin model of atherosclerosis. J Pharm Pharmacol. 2025;77(10):1414\u201325. https:\/\/doi.org\/10.1093\/jpp\/rgaf051.","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"7938_CR41","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1186\/s12872-025-04890-7","volume":"25","author":"Z Wang","year":"2025","unstructured":"Wang Z, Liu S, Shi J, et al. Empagliflozin ameliorates RSL3-induced ferroptosis in vascular endothelial cells via the NRF2\/HO-1 pathway. BMC Cardiovasc Disord. 2025;25(1):437. https:\/\/doi.org\/10.1186\/s12872-025-04890-7.","journal-title":"BMC Cardiovasc Disord"},{"issue":"7","key":"7938_CR42","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3390\/cells14070507","volume":"14","author":"M Kloza","year":"2025","unstructured":"Kloza M, Krzy\u017cewska A, Koz\u0142owska H, Budziak S, Baranowska-Kuczko M. Empagliflozin Plays Vasoprotective Role in Spontaneously Hypertensive Rats via Activation of the SIRT1\/AMPK Pathway. Cells. 2025;14(7):507.","journal-title":"Cells"},{"key":"7938_CR43","doi-asserted-by":"publisher","first-page":"1151244","DOI":"10.3389\/fphar.2023.1151244","volume":"14","author":"OD Vera","year":"2023","unstructured":"Vera OD, Wulff H, Braun AP. Endothelial KCa channels: Novel targets to reduce atherosclerosis-driven vascular dysfunction. Front Pharmacol. 2023;14:1151244. https:\/\/doi.org\/10.3389\/fphar.2023.1151244.","journal-title":"Front Pharmacol"},{"key":"7938_CR44","doi-asserted-by":"publisher","first-page":"116211","DOI":"10.1016\/j.intimp.2026.116211","volume":"173","author":"Y Zhang","year":"2026","unstructured":"Zhang Y, Su J, Deng Y, et al. Poliumoside attenuates endothelial senescence and atherosclerosis by regulating MKRN2-mediated autophagy via the PI3K\/AKT\/ mTOR pathway. Int Immunopharmacol. 2026;173:116211. https:\/\/doi.org\/10.1016\/j.intimp.2026.116211.","journal-title":"Int Immunopharmacol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07938-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07938-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07938-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:11:36Z","timestamp":1788268296000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-026-07938-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":44,"alternative-id":["7938"],"URL":"https:\/\/doi.org\/10.1007\/s10557-026-07938-8","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"14 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The animal studies adhered to ethical standards and received approval from the Animal Ethics Committee of Hebei General Hospital (approval No. 2025-DW-090).","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":3,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}